Dashboard
Poor long term growth as Net Sales has grown by an annual rate of -1.11% and Operating profit at -17.05% over the last 5 years
Flat results in Sep 25
With ROE of 6.6, it has a Very Expensive valuation with a 1.3 Price to Book Value
Despite the size of the company, domestic mutual funds hold only 0.04% of the company
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 2,405 Cr (Small Cap)
20.00
40
0.96%
-0.01
6.62%
1.37
Total Returns (Price + Dividend) 
Latest dividend: 4 per share ex-dividend date: Feb-18-2025
Risk Adjusted Returns v/s 
Returns Beta
News

IOL Chemicals & Pharmaceuticals Sees Mixed Technical Signals Amid Sideways Momentum
IOL Chemicals & Pharmaceuticals is currently exhibiting a shift in price momentum, with technical indicators signalling a transition from a mildly bullish trend to a sideways pattern. The stock’s recent performance and technical parameters reveal a complex interplay of bullish and bearish signals across various timeframes, reflecting a nuanced market assessment for this pharmaceutical sector player.
Read More
IOL Chemicals & Pharmaceuticals Sees Shift in Technical Momentum Amid Mixed Indicator Signals
IOL Chemicals & Pharmaceuticals has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a complex interplay of technical indicators, including the MACD, RSI, moving averages, and Bollinger Bands, which together paint a nuanced picture of the stock’s current market dynamics.
Read More
IOL Chemicals & Pharmaceuticals: Analytical Perspective Shift Amid Mixed Financial and Technical Signals
IOL Chemicals & Pharmaceuticals has experienced a revision in its market assessment following a detailed analysis of its quality, valuation, financial trends, and technical indicators. The recent evaluation reflects a nuanced view of the company’s current position within the Pharmaceuticals & Biotechnology sector, highlighting both challenges and areas of stability amid evolving market conditions.
Read More Announcements 
EDQM Issued CEP Certificate For MINOXIDIL
05-Dec-2025 | Source : BSECEP Certificate for MINOXIDIL
Announcement under Regulation 30 (LODR)-Newspaper Publication
26-Nov-2025 | Source : BSENewspaper publication
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19-Nov-2025 | Source : BSEEarning call transcript
Corporate Actions 
No Upcoming Board Meetings
IOL Chemicals & Pharmaceuticals Ltd has declared 40% dividend, ex-date: 18 Feb 25
IOL Chemicals & Pharmaceuticals Ltd has announced 2:10 stock split, ex-date: 11 Mar 25
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (0.02%)
Held by 60 FIIs (2.25%)
Maya Devi Polycot Limited (21.54%)
Vasudeva Commercials Limited (7.94%)
29.97%
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 2.87% vs 4.53% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -11.67% vs 7.99% in Jun 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 8.86% vs -7.25% in Sep 2024
Growth in half year ended Sep 2025 is 30.09% vs -41.34% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is -4.75% vs -0.06% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -34.79% vs 43.64% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is -2.51% vs -3.80% in Mar 2024
YoY Growth in year ended Mar 2025 is -24.82% vs -3.39% in Mar 2024






